1. Home
  2. SRRK vs DUOL Comparison

SRRK vs DUOL Comparison

Compare SRRK & DUOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

HOLD

Current Price

$47.76

Market Cap

6.8B

Sector

Health Care

ML Signal

HOLD

Logo Duolingo Inc.

DUOL

Duolingo Inc.

HOLD

Current Price

$122.25

Market Cap

5.9B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRRK
DUOL
Founded
2012
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
5.9B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
SRRK
DUOL
Price
$47.76
$122.25
Analyst Decision
Strong Buy
Buy
Analyst Count
13
18
Target Price
$56.17
$176.69
AVG Volume (30 Days)
1.2M
1.0M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
355.85
EPS
N/A
0.89
Revenue
N/A
$1,037,589,000.00
Revenue This Year
N/A
$18.93
Revenue Next Year
$534.24
$14.02
P/E Ratio
N/A
$135.58
Revenue Growth
N/A
38.71
52 Week Low
$27.07
$87.89
52 Week High
$58.49
$468.00

Technical Indicators

Market Signals
Indicator
SRRK
DUOL
Relative Strength Index (RSI) 39.63 47.85
Support Level $45.46 $102.19
Resistance Level $48.23 $136.48
Average True Range (ATR) 2.44 6.33
MACD -1.01 -1.45
Stochastic Oscillator 6.24 26.87

Price Performance

Historical Comparison
SRRK
DUOL

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

About DUOL Duolingo Inc.

Duolingo Inc is a technology company that develops a mobile learning platform to learn languages. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated, master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue: time-based subscriptions, in-app advertising placement by third parties, the Duolingo English Test, and In-App purchases. Geographically, the company generates revenue from its customers in the United States and other markets.

Share on Social Networks: